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Abstract
One of the current challenges in the systemic delivery of nanoparticles in cancer therapy applications is the lack
of effective tumor localization. Iron oxide nanoparticles coated with crosslinked dextran were functionalized with the
tumor homing peptide CREKA, which binds to fibrinogen complexes in the extracellular matrix of tumors. This allows
for the homing of these nanoparticles to tumor tissue. The iron oxide nanoparticle core allows for particle heating
upon exposure to an alternating magnetic field (AMF) while the dextran coating stabilizes the particles in suspension
and decreases the cytotoxicity of the system. Magnetically mediated hyperthermia (MMH) allows for the heating of
tumor tissue to increase the efficacy of traditional cancer treatments using the iron oxide nanoparticles. While MMH
provides the opportunity for localized heating, this method is currently limited by the lack of particle penetration into
tumor tissue, even after effective targeted delivery to the tumor site. The CREKA-conjugated nanoparticles presented
were characterized for their size, stability, biocompatibility, and heating capabilities. The particles were stable in PBS
and media over at least twelve hours, had a hydrated diameter of 52 nm, and generated enough heat to raise
solution temperatures well into the hyperthermia range (41 – 45 °C) when exposed to an AMF. Biocompatibility
studies demonstrated that the particles have low cytotoxicity over long exposure times at low concentrations. A
fibrinogen clotting assay was used to determine the binding affinity of CREKA-conjugated particles, which was
significantly greater than the binding affinity of dextran, only coated iron oxide nanoparticles demonstrating the
potential for this particle system to effectively home to a variety of tumor locations. Finally, it was shown that in vitro
MMH increased the effects of cisplatin compared to cisplatin or MMH treatments alone.
1. Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the United States each year
[1]. Survival without treatment for stage IV NSCLC is 6 months if left untreated and only 9 to 12 months with
treatment. Hyperthermia, the heating of tissue to 41-45 °C, has been shown to be effective in treating lung cancer
when used in conjunction with radiation or chemotherapy [2-4]. While current hyperthermia treatments include
whole body and regional hyperthermia both have several disadvantages, including the burning of healthy tissue,
limited penetration of heat into the body, under-dosage of heat, and complications such as increased heart rate and
increased cardiac output [5-7]. Hyperthermia treatments are further are challenged by deep seated tumors and lack
the ability to penetrate surrounding tissues to raise the tumor tissue into the hyperthermia range [8]. Despite
hyperthermia’s disadvantages, treatment of cancer via hyperthermia in conjunction with cisplatin has resulted in
synergistic effects in regard to cisplatin’s efficacy [9] and sensitization of cisplatin-resistant cell lines [10]. Cisplatin (20
µg/mL or 200 µg/mL) combined with mild incubator-induced hyperthermia at 41 °C was shown to significantly
decrease the surviving fraction of T24 bladder cancer cells in vitro [3]. In another study completed by Hettinga and
coworkers murine tumor cells were mutated in vitro for cisplatin resistance [10]. The cisplatin-resistant cell line was
exposed to cisplatin (0 - 10 µg/mL) for 45 minutes at either 37 °C or 44 °C. Hyperthermia with cisplatin exposure
resulted in a significant decrease in the percentage of cell survival of the cisplatin-resistant cells. A second
experiment demonstrated that the cisplatin-resistant cells were sensitized by hyperthermia by pre-heating the cells
at 44 °C for 10 minutes prior to 45 minutes of cisplatin exposure at 37 °C. This treatment sequence further decreased
the cell survival of the cisplatin-resistant cells [10].
In the presence of an alternating magnetic field (AMF), iron oxide magnetic nanoparticles generate heat and can
induce hyperthermia. Magnetically-mediated hyperthermia, the heating of tissue using heat generated by magnetic
nanoparticles in the presence of an AMF, shows great promise in overcoming the limitations of current hyperthermia
treatments due to the ability of nanoparticles to deliver heat directly to the tumor site, therefore limiting the heat
exposure to surrounding tissues. Iron oxide nanoparticles (IONPs) have the ability to passively or actively target
tumors and in the presence of an external AMF, can generate heat via multiple possible loss mechanisms including
hysteresis, Néel paramagnetic switching, and friction losses from Brownian rotation [8]. IONPs have been studied as
imaging agents, drug delivery devices, and therapeutic enhancers due to their multitude of biological applications,
inherent biocompatibility, magnetic properties, and lack of protein adsorption after proper coating [11]. In all these
applications of IONPs, the main limitation to their efficacy in heating and treating solid tumors is the limitations of
particle localization. Vascularization and the enhanced permeation and retention (EPR) effect allow for passive
targeted delivery of nanoparticles to the periphery of solid tumors. However, active targeting through peptides or

ligands can result in higher local concentrations of nanoparticles and lower systemic concentrations, which is
required for more effective treatment [12].
The proposed particle system functionalized with the peptide CREKA has the ability increase the local
concentration of IONPs compared to non-targeted IONPs, by homing to tumor tissue. CREKA, a tumor homing
peptide, recognizes fibrin-associated plasma proteins, which are overexpressed in cancerous tissue but not in normal,
healthy tissue. The walls of tumor vessels and the interstitial space within tumors contain these fibrin-fibronectin
complexes due to protein seepage from the leaky vasculature of the tumor [12]. It was shown that CREKA can
specifically target fibrin-fibronectin complexes as demonstrated by the peptide’s lack of targeting to syngeneic B16F1
melanoma tumors grown in mice null of fibrinogen or lacking plasma fibronectin but significant homing to syngeneic
B16F1 melanoma tumors in wild-type mice of the same litter [13]. CREKA is a small, linear peptide of five amino
acids, which makes it attractive to use for conjugation with nanoparticles since multiple peptides can be conjugated
to a single nanoparticle [13]. IONPs do not require internalization into cancer cells to be effective at heating the
tumor tissue. Therefore, CREKA conjugation to IONPs is advantageous over other peptides in that it binds to
complexes within the tumor vasculature rather than specific integrins on the surface of cells [12]. Although this study
focuses on CREKA-conjugated IONPs for the treatment of lung cancer, this nanoparticle system has the ability to treat
a multitude of cancerous tumors since it recognizes fibrinogen complexes rather than specific surface integrins,
which are often cell line dependent. CREKA can be conjugated to IONPs through the use of a short linker, N-[amaimidoacetoxy] succinimide ester (AMAS), which then conjugates to primary amines on the particle surface to the
sulfhydryl group via the cysteine of CREKA. The sulfhydryl group on the cysteine is not required for fibrinogen
binding, and can therefore be used to conjugate the peptide to the nanoparticles. By increasing the nanoparticle
concentration within the tumor tissue by active targeting with CREKA, MMH can be more effectively administered.
In this study, peptide-conjugated dextran-coated IONPs for enhanced tumor homing have been developed and
characterized. Physicochemical characterization and in vitro biocompatibility studies are imperative for rationally
develop and understanding a nanoparticle system. Prior to in vivo studies, the properties of this nanoparticle system
such as size, stability, heating profiles, toxicity, and fibrinogen binding affinity need to be optimized. The optimal size
for our nanoparticles is 50 nm, which will allow for tumor penetration and initial accumulation to tumor tissue via the
EPR effect. Stability in media is an important property for systemically delivered nanoparticles, and the heating
properties must be sufficient to induce hyperthermia conditions upon exposure to an AMF. Nanoparticle systems
used for biological applications such as these must be screened for toxicity at low concentrations over long time
frames, and for this specific peptide-conjugated IONP system, the binding affinity of the particles to fibrinogen
complexes was important to verify since fibrinogen complexes within the tumor vasculature are the target of this
system. A proof-of-concept study was then completed to show that this nanoparticle system could be used to
enhance the effectiveness of cisplatin through magnetically mediated hyperthermia. This peptide-conjugated IONP
has optimal physical characteristics for tumor homing via fibrin-fibronectin complexes and ideal heating capabilities,
which can be utilized for the hyperthermia treatment of lung cancer, in combination with chemotherapy.
2. Materials and Methods
2.1 Materials
Iron (III) chloride hexahydrate (FeCl3·6H2O), iron (II) chloride (FeCl2·4H2O), 9 – 11 kDa dextran, epichlorohydrin (ECH),
cisplatin (CDDP), fibrinogen, and thrombin were obtained from Sigma Aldrich (St. Louis, MO). Ammonium hydroxide
(NH4OH) was purchased from EMD Chemicals (Gibbstown, NJ). N-[a-maimidoacetoxy] succinimide ester (AMAS)
linker was obtained from Thermo Scientific (Rochester, NY). CREKA peptide conjugated with 5-FAM-aminohexanoic
acid (FAM-CREKA) was custom ordered through Biomatik (Cambridge, Ontario). Fetal bovine serum (FBS) was
purchased from Fisher Scientific (Florence, KY). Dulbecco’s Modified Eagle Medium (DMEM), pen-strep, L-glutamine,
Fungizone®, and sodium pyruvate were all purchased from Invitrogen (Grand Island, NY), and trypsin was purchased
from American Type Culture Collection (ATCC, Manassas, VA). DMSO, 190 proof ethanol, PBS. All materials were used
as received.

2.2 Crosslinked dextran coated iron oxide nanoparticle synthesis
A modified one-pot co-precipitation method [14] was used to prepare dextran coated IONPs. FeCl3·6H2O and
FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams, respectively) and dissolved in 25 mL
deionized (DI) water and sealed in a three-neck flask under vigorous stirring and an inert nitrogen environment. 11
grams of dextran was solubilized in 50 mL of DI water and added to the three-neck flask. The solution was heated to
85 °C at which 5 ml of NH4OH was injected into the vessel. The reaction was carried out for 1 hour at 85 °C. The
particles were centrifuged at 1000 rpm for 10 minutes to remove large agglomerates. The remaining particles were
then dialyzed against DI water for 24 hours. Dextran coated IONPs were crosslinked using ECH for increased thermal
stability [15]. The particle colloid (9 mL, 1 mmol Fe) was added to 9 mL 5M NaOH and 2 mL ECH. The reaction was
carried out for 24 hours at room temperature under continuous agitation. The particle colloid was then dialyzed
against DI water for 24 hours to remove excess ECH. Crosslinked IONPs were then aminated to allow for peptide
conjugation. This was accomplished by reacting 0.2 mL of 30% ammonium hydroxide with the particle colloid (5 mL,
0.2 mmol Fe) for 24 hours at room temperature under continuous agitation. The particles were then dialyzed against
DI water for 24 hours.
2.3 CREKA conjugation of iron oxide nanoparticles
Amine conjugated IONPs were further conjugated with AMAS (N-[a-maleimidoacetoxyl]succinimide ester) linker. The
primary amines on the nanoparticles react with the N-hydroxysuccinimide of the linker, and CREKA can then be
conjugated to the particle surface by reacting the sulfhydryl group on the cysteine with the maleimide group of the
linker. Particles were resuspended at a concentration of 1 mg Fe/mL in PBS and 2.5 mg AMAS per 2 mg Fe were
dissolved in DMSO prior to addition to the nanoparticle suspension [13]. After the AMAS addition under vortexing,
the reaction was carried out for 40 minutes at room temperature. Particles were then washed three times with PBS
on 100,000 MWCO cellulose Millipore filtration columns. FAM-CREKA was then added to the particle suspension at
25 mg per 4 mg Fe [13]. Particles were incubated overnight at 4°C and washed again with PBS. To serve as a control
for the CREKA-conjugated IONPs, fluorescein isothiocyanate (FITC) was conjugated to amine groups on crosslinked
dextran IONPs. FITC was added in a 1:10 molar ratio to iron oxide (0.434 mmol Fe3O4 and 0.0434 mmol FITC) and
dissolved in 5 mL ethanol. The reaction was carried out for six hours at room temperature. The particles were then
washed with DI water and concentrated using ultrafiltration columns. A summary of the systems investigated can be
seen in Table 1 and a schematic of the systems synthesized can be seen in Figure 1.
2.4 Particle characterization
Transmission electron microscopy (TEM). TEM was completed using a JEOL 2010F system operating at 200 KeV. Iron
oxide nanoparticles were diluted to 200 µg/mL Fe in DI water and then dried on carbon TEM grids prior to analysis.
Ultraviolet (UV)-Visible spectroscopy. The stability of the nanoparticles was analyzed using a CaryWin 50 probe UVvisible spectrophotometer. IONPs were diluted to 200 µg/mL Fe in PBS or DMEM with 10% FBS. Sample absorbance
was read at 540 nm over 12 hours.
Thermogravimetric analysis (TGA). TGA was used to quantify the mass percent of the iron oxide core in the particle
systems using a Netzsch Instruments STA 449A system. Approximately 5 mg of particle sample was heated at a rate
of 5 °/minute. At 100 °C, the sample was held isothermally for 20 minutes to vaporize residual water. The samples
were heated at 5 °/minute until reaching 500 °C where they were held isothermally for an additional 20 minutes. The
reported mass loss reported was the actual mass loss normalized to the initial sample mass after isothermal heating
at 100 °C.
Dynamic light scattering (DLS). DLS measurements were obtained using a Beckman Coulter Delsa Nano C particle
analyzer. Nanoparticle solutions were diluted to 200 µg/mL and were sonicated in a water bath prior to size analysis.
Alternating magnetic field (AMF) heating. The nanoparticle heating profiles were obtained using a custom made
Taylor Winfield magnetic induction source and the temperature was measured with a fiber optic temperature sensor
(Luxtron FOT Lab Kit from LumaSense). Nanoparticle suspensions were diluted in DI water to a concentration of 5
mg/ml iron oxide. One milliliter of suspension was placed in a 2 ml microcentrifuge tube and placed in the center of
the AMF induction coil. The suspension was heated at a field strength of 58 kA/m and 292 kHz frequency until the
temperature of the suspension reached equilibrium. The specific absorption rate (SAR) values of the nanoparticle
suspensions were then calculated using the initial temperature change normalized to the mass of nanoparticles
present.

2.5 Cytotoxicity analysis of particle systems
A549 lung carcinoma cells obtained from ATCC were cultured from passages 5 - 10 in DMEM supplemented with 10%
FBS, 10 μg/ml Fungizone®, 2 μg/ml penicillin-streptomycin, and 4mM L-glutamine. Cells were seeded into 96-well
plates at 4,000 cells/well and incubated for 24 hours. The cells were then exposed to nanoparticles in complete cell
media at concentrations of 50, 100, 350, and 500 µg Fe/ml. Cytotoxicity was determined using a calcein red
fluorescent stain (1 µM, λex=540nm and λem=590nm) after 24 and 48 hours. Cell viability was analyzed using a Biotek
SynergyMx microplate reader and the fluorescence of the cells exposed to the nanoparticle solutions was normalized
to the fluorescence of the control cells.
2.6 CREKA and CREKA IONP binding affinity to fibrinogen clots
To synthesize fibrinogen clots, 75 µL of fibrinogen solution (2 mg/mL) in 0.9% NaCl was added to a 96-well plate. 30
µL of a 2.5 U/mL thrombin solution in 0.9% NaCl was subsequently added to the same 96-well plates. The plates were
placed in an incubator shaker at 37°C for 5 minutes, and then gels were formed after four hours incubation at 37°C.
Binding affinity of fluorescently labeled CREKA conjugated IONPs (CREKA-IONP) was compared to the binding affinity
of unconjugated CREKA (CREKA only) and FITC conjugated iron oxide nanoparticles without CREKA (FITC-IONP).
CREKA-IONP and FITC-IONP systems were diluted by taking 5, 10, 25, and 50 µL of nanoparticle solution and diluting
to a total volume of 50 µL with DI water. The exact nanoparticle concentration was not necessary due to taking the
fluorescence ratio of the bound to free particles at the same concentration. CREKA was diluted to 50, 100, 250 and
500 µM. 50 µL of solution (particle or CREKA only) was added to each clot. After one hour, half of samples were
washed twice with 120 µL of DI water to remove any CREKA or IONPs not bound to the fibrinogen clots and the
fluorescence of the plate was read on the microplate reader (λex=488 nm and λem=520 nm). The bound CREKA or FITC
fluorescence (washed gels) was normalized to the corresponding free (unwashed gels) solution for each sample.
2.7 In vitro magnetically mediated hyperthermia
One mL of A549 lung carcinoma cells (passage 15) was suspended in complete cell culture media in a 1.5 ml
microcentrifuge tube at a concentration of 300,000 cells. The vials were then centrifuged at 800 x g for 5 minutes to
pellet the cells. The media supernatant was removed and the cells were resuspended in 1 mL of the respective
treatment solutions. The six treatments are outlined in Table 2. Hyperthermia treatments (indicated by AMF
exposure) lasted 30 minutes and all controls were also exposed to treatments or experimental conditions (i.e. room
temperature) for 30 minutes. After treatment, the vials were centrifuged at 800 x g for 5 minutes, the treatment
solution was removed, and replaced with fresh media. A second centrifugation cycle was completed to further wash
the cells of the treatment solutions. The treated cells were then seeded into 48-well plates at 30,000 cells/mL (250
µL/well). The viability of the cells was analyzed 48 and 72 hours post-treatment using a calcein AM assay (2 µM,
λex=494 nm and λem=517 nm) analyzed by a microplate reader. The fluorescence of the cells exposed to the various
treatments was normalized to the fluorescence of the control cells at each time point.
2.8 Statistical analysis
Statistical analysis was completed using Daniel’s XL Toolbox in Microsoft Excel. A 1-way ANOVA test was used to
determine the statistical differences of the cytotoxicity analysis and magnetically mediated hyperthermia study. A
student t-test was used to determine the statistical differences of the fibrinogen binding study.

3. Results and Discussion
3.1 Particle characterization
The iron oxide cores of the nanoparticles exhibited diameters of 5 – 13 nm as shown by the TEM images in Figure
2. The clustering of the iron oxide suggests that multiple cores are encapsulated by the dextran coating for each
nanoparticle. Due to the low density of the dextran coating, no differences were observed between the TEM images
of the Fe3O4+Dx and Fe3O4+Dx-ECH nanoparticles. As seen in Table 1, size analysis indicated that the hydrated
diameters of the nanoparticle systems were approximately 52 nm. Particles of this size have been shown to
extravasate into tumor tissue and have been used in passive tumor targeting by taking advantages of the leaky
vasculature of the tumor and the enhanced permeation and retention effect [16, 17].
Ensuring the stability of nanoparticles in various types of solutions over time is very important, especially for the
systemic delivery of therapeutics. Particle-particle interactions can induce aggregation and particle settling which can
adversely affect the properties of the nanoparticles, such as heating capabilities and tumor targeting. Particle
aggregates greater than 200 nm not only settle out of solution, but also attract opsonin proteins in vivo which label
the particles for removal through the reticuloendothelial system (RES) [16]. Through UV-visible spectroscopy it was
shown that the nanoparticles were stable in both PBS and DMEM for each stage of particle synthesis over a time
period of 12 hours (Figure 3). A normalized absorbance of one indicates minimal to no particle settling in solution. A
slight increase in particle stability in PBS after crosslinking the dextran with epichlorohydrin was observed, which was
expected due to an increase in the thermal stability of the dextran coating. Overall, these results indicate the high
stability of the evaluated particle systems in several solutions, which may be an indication of increased particle
stability for systemic delivery for the treatment of lung cancer using MMH.
Thermogravimetric analysis was used to confirm the presence of the dextran coating on the iron oxide
nanoparticles. This showed that the coating accounted for 59 - 64% of the nanoparticle mass prior to CREKA
conjugation. The coating weight percentage was calculated by subtracting the final mass fraction from the initial
normalized mass. As depicted in Figure 4, crosslinking of the dextran coating with ECH was confirmed by the shift of
the mass loss profile to the right where an increase in the temperature at which the greatest mass loss occurred
shifted from 285 °C (Fe3O4+Dx) to 306 °C, (Fe3O4+Dx-ECH and Fe3O4+Dx-ECH-Amine), indicating a greater thermal
stability of the coating. The observed single drop in particle mass with increasing temperature confirms a single
dextran layer on the surface of the particles, as this abrupt change in weight has been previously associated with a
monolayer of dextran [18] . The dextran coating of the final CREKA-IONP only accounted for 30% of the nanoparticle
mass due to the dissolution of AMAS linker in DMSO during the final CREKA conjugation process. Dextran has a very
high affinity for DMSO resulting in any free or weakly bound dextran solubilizing in the DMSO and being washed from
the nanoparticle system during the washing process. As indicated by UV-visible spectroscopy, the CREKA-IONP
remained stable in PBS and DMEM indicating that dextran was still present on the surface of the particles.
3.2 Remote controlled heating of iron oxide magnetic nanoparticles via AMF
In the presence of an AMF (58 kA/m, 292 kHz), the iron oxide nanoparticle systems (5 mg/mL Fe3O4) heated the
bulk solution into or above the hyperthermia range (41 - 45 °C) as seen in Figure 5. Fe3O4+Dx, Fe3O4+Dx-ECH, and
Fe3O4+Dx-ECH-Amine particles heated to 41 °C within 300 seconds. The final CREKA-IONP system took longer to reach
the hyperthermia range and heated to a lower final temperature than the other systems. The iron concentration of
the nanoparticles was usually determined using an iron assay prior to dilution for heating in the AMF. However, the
exact iron concentration of the CREKA-IONP could not be determined due to low volume of particles so the initial
iron concentration in the CREKA-IONP prior to washing was used. Therefore, if any iron oxide nanoparticles were lost
in the ultracentrifugation washing steps, the actual iron concentration of the AMF heating samples would be lower
than calculated, accounting for the lower final temperature and decreased initial slope of the heating profile. SAR
values were calculated using the following equation:
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where Cp,Fe is the heating capacity of iron, mFe the mass of iron, Cp,H2O the heating capacity of water, mH2O the mass of
water, and dT/dt the initial slope of the heating profile. The SAR values are reported in Table 1 and indicate the

energy being produced per gram of iron oxide. The lower SAR value for the CREKA-IONP is accounted for by the
previous explanation of the concentration discrepancy.
3.3 Cytotoxicity analysis of particles
Cytotoxicity of the particles produced in each step in the particle synthesis was evaluated using A549 lung
carcinoma cells. A549 cells were exposed to low doses of iron oxide nanoparticles for 24 and 48 hours, and the
viability of the cells was analyzed using a calcein AM stain. As depicted in Figure 6, the particles exhibited no toxicity
(at least 100% viability) after 24 hours. Dextran is colloidal, hydrophilic, water-soluble substance which is inert in
biological systems, therefore decreasing protein adsorption to the nanoparticle surface which would lead to toxicity
[19]. After 48 hours, the particles were still mostly non-toxic at these concentrations, however, there was a
significant difference between the control and the CREKA-IONP at 100, 350, and 500 µg Fe/mL as determined via a 1way ANOVA test. However, the viability of the A549 cells after exposure to these concentrations for 48 hours is still
above 80%, indicating that the particles are minimally toxic even though the difference from the control is significant.
3.4 Fibrinogen binding affinity
CREKA-IONPs were shown to bind to fibrinogen clots with a significantly greater bound-to-free fluorescence ratio
than fluorescently tagged iron oxide nanoparticles (FITC-IONP) (Table 2). The bound-to-free fluorescence ratios of
free CREKA and CREKA-IONPs were not significantly different, indicating that conjugation to the nanoparticle surface
does not inhibit the binding properties of CREKA. The sulfhydryl group on the cysteine of CREKA is not required for
binding to fibrinogen clots. Therefore, conjugation to the nanoparticle surface through a Michael addition reaction
with an AMAS linker does not influence the fibrinogen binding properties of CREKA. These results indicate that CREKA
can be functionalized to the IONP in order to localize the nanoparticles at the tumor site through binding with
fibrinogen complexes in the extracellular matrix. CREKA-IONPs do not bind to specific integrins on the cell surface
providing the opportunity to target a wider range of cancers. Additionally, CREKA-IONPs have resulted in amplified
homing by inducing localized tumor clotting in vivo [13]. These clots then attract more CREKA-IONPs and the cycle
continues. This amplified homing of CREKA to the fibrin complexes within the tumor, make it attractive for localizing
high concentrations of IONPs at the tumor site for magnetically mediated hyperthermia.
3.5 Magnetically-mediated hyperthermia
The heating properties of the magnetic iron oxide nanoparticles were utilized to induce in vitro hypothermia
conditions on A549 lung carcinoma and the effects of combined MMH and cisplatin treatments were evaluated since
cisplatin is known to increase MMH efficacy at elevated temperatures [4, 20]. Five treatments plus a control were
evaluated as seen in Table 2 and cell viability 48 and 72 hours post-treatment was determined to allow time for
cellular response to the treatments. After 48 hours (Figure 7), there is no significant difference between MMH
treatment alone and combined cisplatin and MMH treatment (CDDP+MMH). However, at this time point there is also
no difference between the viability of cells exposed to cisplatin and the control, indicating that the cells have not
responded to the cisplatin treatment. As seen in Figure 8, after 72 hours there is a significant difference (p < 0.01)
between the viability of cells exposed to MMH treatment alone and combined cisplatin and MMH treatment
(CDDP+MMH). At this time point, the cells have responded to the cisplatin treatment, as shown by the significantly
decreased viability of cells exposed to cisplatin compared to the control. Additionally, cell morphology dramatically
changes when the cells are treated with cisplatin combined with MMH compared to either treatment alone. Images
in Figures 7 and 8, show the cell with blebs, or localized decoupling of the cytoskeleton from the cell membrane,
which is an indicator of apoptosis, or programmed cell death [21]. Therefore, cisplatin combined with MMH has a
significantly greater effect on cell viability than either treatment alone.
Additional analysis was completed to determine the type of effect of MMH and cisplatin had on A549 cells after
72 hours using the following equations [9]: synergistic, [MMH + CDDP] < [MMH] x [CDDP]/100; additive, [MMH +
CDDP] = [MMH] x [CDDP]/100; sub-additive, [MMH] x [CDDP]/100 < [MMH + CDDP] < [MMH]; if [MMH] < [CDDP];
interference, [MMH] < [MMH + CDDP] < [CDDP], if [MMH] < [CDDP]; and antagonistic, [CDDP] < [MMH + CDDP], if
[MMH] < [CDDP], where [MMH] represents the cell viability percentage exposed to magnetically mediated
hyperthermia alone, [CDDP] represents the cell viability percentage exposed to cisplatin alone, and [MMH+CDDP]
represents the cell viability percentage exposed to combined magnetically mediated hyperthermia and cisplatin. 72

hours after treatment, the percent viability of the combined treatment was 23.7 ± 2.9 and [MMH] x [CDDP]/100
equaled 26.2 ± 2.1, where the error represents standard error (n = 12). Therefore, the combined treatment of
hyperthermia and cisplatin was determined to be additive since these values are not significantly different, as
indicated by a student t-test. This analysis was not completed on the 48 hour post-treatment data due to the cell
viability of cisplatin only treatment not being different from the control.
There are several theories as to how the effects of cisplatin are enhanced by hyperthermia. Cisplatin operates by
binding to DNA forming inter- or intra-strand crosslinks and interfering with the transcription DNA for protein
synthesis, therefore preventing cell division, ultimately leading to cell death [22]. In vitro studies have shown that
hyperthermia increases the intracellular concentration of cisplatin [23, 24], and therefore increases the binding of
cisplatin to DNA [25]. Additionally, inhibition of cellular resistance to cisplatin has been observed when combined
with hyperthermia [26]. Hyperthermia results in increased blood flow and vascular permeability allowing for greater
drug uptake and improved oxygenation of the tumor tissue [5]. Hyperthermia has been shown to promote cell death
by increasing the fluidity of membranes causing adverse intracellular and surface events, inactivating microtubule
processes and by enhancing cellular antigen expression or antigen antibody complexation [27]. The efficacy of
hyperthermia alone is not enough to replace any of the current chemotherapy standards, but its effects are sufficient
to enhance the toxic effects of many chemotherapeutics. Therefore, by combining magnetically mediated
hyperthermia and cisplatin, the effective dosage of cisplatin can be decreased, and therefore potentially decreasing
the toxic side effects of the chemotherapeutic.
4. Conclusion
CREKA-conjugated dextran coated iron oxide nanoparticles were successfully developed and characterized for
their use in targeted hyperthermia applications. The nanoparticles have ideal properties for systemic tumor targeting
such as stability in cell culture media and a size of approximately 50 nm. In the presence of an alternating magnetic
field, the particles generated sufficient heat to increase the bulk solution temperature into the hyperthermia range.
CREKA-conjugated nanoparticles were shown to bind to fibrinogen clots with a higher affinity than FITC-conjugated
iron oxide nanoparticles, suggesting that the nanoparticles can be effective at targeting fibrinogen overexpressed in
tumor tissues. The binding affinity of CREKA was not inhibited by conjugation to the iron oxide nanoparticles as
shown by similar bound-to-free ratios of fluorescence. Low concentrations of the nanoparticle systems were nontoxic over long periods of time, indicating that the particles can be used for biological applications. When
magnetically mediated hyperthermia was administered in conjunction with cisplatin, an enhanced cytotoxic effect
was observed compared to cisplatin or hyperthermia alone. This peptide-conjugated nanoparticle system can be
further studied to assess its ability to localize at tumor sites at sufficient concentrations to induce hyperthermia
conditions upon exposure to an external alternating magnetic field.
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Figures

Figure 1. Iron oxide nanoparticle synthesis process ffor the (a) dextran coating, (b) epichlorohydrin crosslinking, (c)
amine conjugation, and (d) conjugated with and AMAS linker, connecting the FAM
FAM-labeled
labeled CREKA to the primary
amine.
Table 1. Nanoparticle systems synthesized
sized and characterized and their abbreviations
abbreviations,, size as analyzed via DLS, and
SAR values from AMF heating. Size of Fe3O4+Dx-ECH-Amine-CREKA
CREKA via DLS could not be completed due to fluorescent
tag but minimal difference from the other systems is expected.
Nanoparticle System
Abbreviation
Size (nm) SAR (W/g)
Dextran coated IONP
Fe3O4+Dx
52 ± 16
81 ± 19
Epichlorohydrin crosslinked dextran coated IONP
Fe3O4+Dx-ECH
56 ± 11
98 ± 16
Amine-conjugated
conjugated crosslinked dextran coated IONP
Fe3O4+Dx-ECH-Amine
52 ± 8
89 ± 9
CREKA-conjugated dextran coated IONP (CREKA
(CREKA-IONP) Fe3O4+Dx-ECH-Amine-CREKA
--66 ± 18
Table 2. Magnetically mediated hyperthermia treatments and controls.
Treatment
Description
Control
Media only
IONP
3 mg/mL Fe3O4 (Fe3O4+Dx-ECH)
MMH
3 mg/mL Fe3O4 plus 30 minutes AMF exposure
CDDP
100 µM
M cisplatin
CDDP+IONP
100 µM
M cisplatin plus 3 mg/mL Fe3O4
CDDP+MMH
100 µM
M cisplatin plus 3 mg/mL Fe3O4 and 30 minutes AMF exposure

Figure 2. TEM images of (a) dextran coated iron oxide nanoparticles (Fe3O4+Dx) and (b) dextran-epichlorohydrin
dextran
crosslinked iron oxide nanoparticles (Fe3O4+Dx-ECH).

Figure 3. Normalized absorbance (at 540 nm) of the iron oxide nanoparticle systems in (a) PBS and (b) DMEM with
10% v/v FBS over 12 hours using UV-visible
visible spectroscopy.

Figure 4. Normalized mass loss of each nanoparticle system in the synthesis process via TGA..

Figure 5. Heating profiles of each nanoparticle system in the synthesis process (5 mg/mL Fe3O4) in the presence of an
alternating magnetic field at 58 kA/m and 292 kHz (n = 3)
3).. The gray box indicates the target hyperthermia range.

Figure 6. Normalized viability of each nanoparticle system in the synthesis process on A549 lung cancer cells after (a)
24 hours of exposure and (b) 48 hours of exposure. Error bars represent standard error (n = 4) and * indicates a
significant difference (p < 0.05) using a 1-way
way ANOVA test.
Table 1. Bound-to-free
ree fluorescence for each system represented by average ± standard error (n = 4). The * indicates
a significant difference to the CREKA-IONP
IONP bound-to-free fluorescence ratio (p<0.05).
System
Bound-to-free fluorescence
CREKA only
0.69 ± 0.03
CREKA-IONP
0.62 ± 0.03
FITC-IONP
0.42* ± 0.04

Figure 7.. Relative viability of A549 lung cancer cells 48 hours post magnetically mediate hyperthermia treatment.
Error bars represent standard error (n = 12
12) and * indicates a significant difference (p < 0.01). Representative images
of A549 cells stained with calcein AM after 48 hours for: (a) Control, (b) IONP, (c)MMH, (d) CDDP,
CDDP (e) CDDP+IONP,
and (f) CDDP+MMH.

Figure 8. Relative viability of A549 lung cancer cells 72 hours post magnetically mediated hyperthermia treatment.
Error bars represent standard error with n = 12 and * indicates a significant difference (p < 0.01). Representative
images of A549 cells stained with calcein AM after 72 hours for: (a) Control, (b) IONP, (c) MMH,
MMH (d) CDDP, (e)
CDDP+IONP, and (f) CDDP+MMH.

